Methods and compositions comprising free fatty acids for the treatment, including prevention, of viral infections, including the treatment of Acute Respiratory Distress Syndrome (ARDS)/. The compositions comprising free fatty acids, optionally linolenic acid, linoleic acid, and/or palmitic acid, may be used in methods for treating viral infections, optionally, coronavirus infections, for example, SARS-CoV, MERS-CoV, and/or SARS-CoV-2/COVID-19, and influenza virus infections, optionally, H1N1 and/or H5N1.

Methods and compositions comprising free fatty acids for the treatment, including prevention, of viral infections, including the treatment of Acute Respiratory Distress Syndrome (ARDS)/. The compositions comprising free fatty acids, optionally linolenic acid, linoleic acid, and/or palmitic acid, may be used in methods for treating viral infections, optionally, coronavirus infections, for example, SARS-CoV, MERS-CoV, and/or SARS-CoV-2/COVID-19, and influenza virus infections, optionally, H1N1 and/or H5N1.

The present disclosure provides hCG variant proteins, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of treating cancer.

The present disclosure provides hCG variant proteins, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of treating cancer.

The present disclosure provides hCG variant proteins, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of treating cancer.

Disclosed herein are new salts and polymorphs of cethromycin for the treatment of diseases due to infection by bacteria and certain protozoans, including, for example, malaria, Babesosis, Toxoplasmosis, diarrheal disease, respiratory disease, sexually transmitted bacterial infections, and some bioterror bacteria, including, for example, plague, tularemia and post-inhalation anthrax. Also disclosed herein are new salts and polymorphs of cethromycin for the treatment of inflammatory diseases, including, for example, pelvic inflammatory disease, and peptic ulcer disease.

Disclosed herein are new salts and polymorphs of cethromycin for the treatment of diseases due to infection by bacteria and certain protozoans, including, for example, malaria, Babesosis, Toxoplasmosis, diarrheal disease, respiratory disease, sexually transmitted bacterial infections, and some bioterror bacteria, including, for example, plague, tularemia and post-inhalation anthrax. Also disclosed herein are new salts and polymorphs of cethromycin for the treatment of inflammatory diseases, including, for example, pelvic inflammatory disease, and peptic ulcer disease.

A compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof;

##STR00001##

in which X, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, Y, and are as described in the claims, for the use thereof in the treatment of bacterial infections including those caused by caused by at least one bacterium of the genus selected from aerobic Gram-positive bacteria; Gram-negative enterobacteria; Gram-negative bacilli; Gram-negative anaerobic bacteria; Gram-positive anaerobic bacteria; mycobacteria and pathogens involved in sexually transmitted infections.

A compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof;

##STR00001##

in which X, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, Y, and are as described in the claims, for the use thereof in the treatment of bacterial infections including those caused by caused by at least one bacterium of the genus selected from aerobic Gram-positive bacteria; Gram-negative enterobacteria; Gram-negative bacilli; Gram-negative anaerobic bacteria; Gram-positive anaerobic bacteria; mycobacteria and pathogens involved in sexually transmitted infections.

The present invention relates to a pharmaceutical composition comprising Diltiazem in a suitable pharmaceutical carrier for its therapeutic use in the prevention and/or treatment of a viral infection caused by the SARS-CoV-2 virus, referred to as COVID-19 disease.